The risk of recurrence was generally low among cervical cancer patients with no high-risk factors who underwent radical surgery without adjuvant therapy.

ERC Advanced Grants worth a total of €721m were awarded to 281 researchers, with UCD's Prof Kylie Jarrett and Dr Barry Wardell among the winners.

Oesophageal adenocarcinoma has an extremely poor prognosis, and improving outcomes via therapy remains particularly challenging in such a heterogeneous cancer. Another avenue for improving outcomes ...

New findings suggest that a PSA level of 0.2 ng/mL or greater can predict a poor prognosis and indicate a possible need for ...

The Motley Fool. DATE Tuesday, June 17, 2025 at 10 a.m. ET CALL PARTICIPANTS Interim Chief Executive Officer and Board Chair ...

Proceeds to fund Phase 1/2 trial of EO2463 OncoMimics™, as a monotherapy or in combination, to treat multiple forms of indolent non-Hodgkin lymphoma (iNHL)$9 million from new investor The Institute ...

I maintain a Buy rating on Zymeworks Inc. stock due to platform promise and upcoming catalysts. However, click for why I am ...

Phase 2 trial results support Isa-KRd as a standard treatment option for patients with high-risk, newly diagnosed multiple myeloma, according to researchers.

There’s reason to remain bullish about Merck’s growth prospects in the long run. And at a discounted price, the stock could ...

FN Media Group News Commentary - The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around the world. The World Health Organization estimates ...